Urinary epidermal growth factor in patients with gliomas: significance of the factor as a glial tumor marker.
Epidermal growth factor (EGF) content in urine from patients with glial tumors was examined by radioimmunoassay techniques with labeled human EGF and its rabbit EGF polyclonal antibody. There was no cross-reaction with transforming growth factor-alpha, which has a common receptor with EGF. Forty glial tumors were divided into three groups according to the clinical stage: Samples from Group A patients were obtained before therapy and/or after biopsy; in these patients a large volume of tumor was apparent on computerized tomography (CT). Group B samples were obtained after gross total removal of the tumor and/or chemo- and radiation therapy; these patients showed a small volume of residual tumor on CT. Samples from Group C patients were obtained after gross tumor total removal and/or chemo- and radiation therapy; no tumor was detected on CT scans in these patients. Urinary EGF levels in Group A samples were statistically significantly higher than in samples from healthy individuals (p < 0.001), Group B patients (p < 0.10), and Group C patients (p < 0.02). In addition, high-grade glial tumors in Group A cases showed a significantly higher level of urinary EGF than low-grade tumors in Group A patients (p < 0.05), or patients with meningioma (p < 0.02), metastatic brain tumor (p < 0.05), and cerebral infarction (p < 0.001). Longitudinal changes of urinary EGF levels in glioma patients mostly synchronized with the clinical course and therapeutic interventions. Therefore, urinary EGF, as a glial tumor marker, may be of practical value for diagnosing a malignant glioma and evaluating for the efficacy of chemo- and radiation therapy.
Kanno
H
H
Department of Neurosurgery, Yokohama City University, Kanagawa Cancer Center, Japan.
Chiba
Y
Y
Kyuma
Y
Y
Hayashi
A
A
Abe
H
H
Takada
H
H
Kim
I
I
Yamamoto
I
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D001932:Brain Neoplasms / Q000628:therapy / Q000652:urine*; D004815:Epidermal Growth Factor / Q000652:urine*; D005260:Female; D005910:Glioma / Q000628:therapy / Q000652:urine*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay
D014408:Biomarkers, Tumor; D004815:Epidermal Growth Factor